Fate Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a collaboration revenue of $1.7 million, a decrease from $3.1 million in the same period last year. For the nine months ending September 30, 2025, total collaboration revenue was $5.3 million, down from $11.8 million in 2024. The decline in revenue is attributed to the absence of significant milestone payments that were recognized in the previous year, particularly a $5 million clinical development milestone from a collaboration with Ono Pharmaceutical Co., Ltd.
The company’s operating expenses for the third quarter were $36.5 million, a reduction from $55.5 million in the prior year. This decrease was primarily driven by lower research and development expenses, which fell to $25.8 million from $34.7 million, and a significant drop in general and administrative expenses, which decreased to $10.6 million from $20.8 million. The overall net loss for the quarter was $32.3 million, compared to a net loss of $47.7 million in the same quarter of 2024. For the nine-month period, the net loss was $103.9 million, down from $134.1 million in the previous year.
Fate Therapeutics has undergone strategic restructuring to streamline operations and reduce costs, which included a workforce reduction announced in August 2025. The company incurred $1.1 million in severance and related costs during the third quarter as part of this restructuring effort. As of September 30, 2025, the company had cash and cash equivalents totaling $40.6 million, alongside short-term investments of $174.8 million, reflecting a decrease in total assets from $440.7 million at the end of 2024 to $343.7 million.
Operationally, Fate Therapeutics continues to focus on its proprietary induced pluripotent stem cell (iPSC) technology platform, which is central to its product development pipeline. The company is advancing multiple iPSC-derived cell product candidates through clinical trials, although it has not yet generated revenue from product sales. The company’s workforce as of the end of September 2025 was reduced as part of its restructuring, although specific headcount figures were not disclosed.
Looking ahead, Fate Therapeutics anticipates continued operating losses as it invests in the development of its product candidates and seeks regulatory approvals. The company plans to finance its operations through public or private equity, debt securities, and collaboration arrangements. However, it acknowledges the challenges of securing additional funding and the potential impact of global economic conditions on its financial stability and operational capabilities.
About FATE THERAPEUTICS INC
Fate Therapeutics is a biopharmaceutical company developing off-the-shelf cellular immunotherapies using proprietary induced pluripotent stem cell (iPSC) technology. Its focus includes engineered T-cell and natural killer (NK) cell products for autoimmune diseases and solid tumors. The company leverages innovative synthetic controls, gene editing, and scalable manufacturing to create targeted, durable, and accessible cell therapies aimed at addressing unmet medical needs across cancer and autoimmune indications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.